Vetter Appoints Oliver Albrecht as Managing Director
News Apr 09, 2015
Vetter has announced that the company’s Advisory Board unanimously appointed Oliver Albrecht as a new Managing Director effective April 1, 2015. Albrecht replaces Max Horn as a Vetter Managing Director who left the company in June 2014.
Oliver Albrecht has more than 20 years of experience managing international, medium-sized listed companies both as a Managing Director and as Chief Financial Officer in a wide variety of industries including banking, automotive, and mechanical engineering.
In recent years, Oliver held the position as Chief Financial Officer for SHW AG headquartered in Aalen, Germany and acted also as an independent consultant for mid-sized companies.
A seasoned finance and operations executive, Oliver’s previous positions include senior posts at companies including Chief Financial Officer for centrotherm photovoltaics AG and as a Director in the Financial and Banking Sector. He holds a diploma in Business from the University of Mannheim, Germany.
“We undertook a rigorous selection process to identify the right person to help lead our company forward,” said Udo J. Vetter, Chairman of the company’s Advisory Board and member of the owner family. “Oliver’s vast experience in a variety of industries, combined with his deep knowledge of achieving operational and financial excellence will be a tremendous asset to Vetter.”
In his new role as Managing Director, Albrecht will be responsible for two of the eight company divisions, the first of which is comprised of Finance, Controlling and IT. The second division includes Corporate Development, Legal and Corporate Compliance.
Peter Soelkner and Thomas Otto, Vetter’s two Managing Directors added, “we are happy to have this Managing Director position filled with someone having the background that Oliver Albrecht offers. We are pleased to assist our new colleague in any way possible to make his start at Vetter both promising and productive. We wish him success in his new position.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE